患者来源儿童脑肿瘤模型生物样本库的建立与分子特征
通过儿童肿瘤协作组ACNS02B3研究,建立并全面表征了30个患者来源的原位异种移植模型和7个细胞系,覆盖14个儿童脑肿瘤分子亚组。这些模型在组织学、免疫组化、基因表达、DNA甲基化、拷贝数及突变谱上与原发肿瘤一致,体内药物敏感性分析显示靶向治疗反应与特定分子亚组和遗传改变相关。该资源为研究致癌驱动因素和评估新治疗策略提供了前所未有的平台。
要点
- 建立了30个患者来源原位异种移植模型和7个细胞系,覆盖14个儿童脑肿瘤分子亚组。
- 模型在组织学、分子特征上与原发肿瘤高度一致。
- 靶向药物体内敏感性关联特定分子亚组和遗传改变。
核心结论
- 患者来源原位异种移植模型和细胞系能代表原发儿童脑肿瘤的生物学异质性,可用于研究致癌驱动因素和评估新治疗策略。
研究设计与样本
- 通过儿童肿瘤协作组ACNS02B3研究,生成并全面表征30个患者来源原位异种移植模型和7个细胞系,代表14个儿童脑肿瘤分子亚组。
主要发现
- 模型在组织学、免疫组化、基因表达、DNA甲基化、拷贝数和突变谱上与原发肿瘤一致。
- 体内靶向药物敏感性与特定分子亚组和遗传改变相关。
临床怎么用
- 该模型资源可用于临床前研究,以评估针对特定分子亚组的靶向治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Brain tumors are the leading cause of cancer-related death in children. Genomic studies have provided insights into molecular subgroups and oncogenic drivers of pediatric brain tumors that may lead to novel therapeutic strategies. To evaluate new treatments, better preclinical models adequately reflecting the biological heterogeneity are needed. Through the Children's Oncology Group ACNS02B3 study, we have generated and comprehensively characterized 30 patient-derived orthotopic xenograft models and seven cell lines representing 14 molecular subgroups of pediatric brain tumors. Patient-derived orthotopic xenograft models were found to be representative of the human tumors they were derived from in terms of histology, immunohistochemistry, gene expression, DNA methylation, copy number, and mutational profiles. In vivo drug sensitivity of targeted therapeutics was associated with distinct molecular tumor subgroups and specific genetic alterations. These models and their molecular characterization provide an unprecedented resource for the cancer community to study key oncogenic drivers and to evaluate novel treatment strategies.
引用
- Brabetz S, Leary SES, Gröbner SN, et al. A biobank of patient-derived pediatric brain tumor models. Nat Med. 2018. PMID: 30349086. doi:10.1038/s41591-018-0207-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。